Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haploidentical Related Hematopoietic



Status:Recruiting
Conditions:Blood Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any - 75
Updated:1/18/2019
Start Date:January 24, 2017
End Date:January 2021
Contact:Timothy Krepski
Email:tkrepsk1@fairview.org
Phone:612-273-2800

Use our guide to learn which trials are right for you!

Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies

This is a single institution phase II study of a reduced intensity conditioning (RIC)
followed by a haploidentical hematopoietic cell transplant (haplo-HCT) in persons with
diagnosis of hematologic malignancy. Conditioning will consists of fludarabine,
cyclophosphamide, melphalan and total body irradiation (TBI) preparative regimen with a
melphalan dose reduction for patients ≥55 years old and those with HCT Comorbidity Index (CI)
>3. This study uses a two-stage phase II design with accrual goal of 44 patients, using 22
patients separately for arms A and B.


Inclusion Criteria:

- Karnofsky performance status of ≥70% or Lansky play score ≥ 70%

- A related haploidentical bone marrow donor with up to 2 or 3 HLA locus-mismatches

- The donor and recipient must be HLA identical for at least one haplotype (using high
resolution DNA based typing) at the following genetic loci: HLA-A, HLA-B, HLA-C, and
HLA-DRB1.

- Adequate liver and renal function

- Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left
ventricular ejection fraction ≥ 40%

- Diffusion capacity corrected (DLCOcorr) > 40% predicted, and absence of O2
requirements

- > 6 months after prior autologous transplant (if applicable)

- Agrees to use contraception during study treatment

- Voluntary written consent (adult or parent/guardian with presentation of the minor
information sheet, if appropriate)

Exclusion Criteria:

- < 70 years with an available 5-6/6 HLA-A, B, DRB1 matched sibling donor

- Pregnancy or breastfeeding

- Evidence of HIV infection or known HIV positive serology

- Current active and uncontrolled serious infection

- Acute leukemia in morphologic relapse/persistent disease defined as > 5% blasts in
normocellular bone marrow OR any % blasts if blasts have unique morphologic markers
(e.g. Auer rods).

- CML in blast crisis

- Large cell lymphoma, mantle cell lymphoma and Hodgkin disease that is progressive on
salvage therapy.

- stable non-bulky disease is acceptable.

- Active central nervous system malignancy

Criteria For Donor Selection:

- Donors must be HLA-haploidentical relatives of the patient, defined as having a shared
HLA haplotype between donor and patient at HLA-A, -B, -C, and -DRB1.

- Eligible donors (14-70 years old) include biological children, siblings or half
siblings, or parents, able and willing to undergo bone marrow harvesting.

- For donors <18 years, the maximum recipient weight (actual body weight) should not
exceed 1.25 times the donor weight (actual body weight)1 In addition, bone marrow
product volume should be limited to 20 ml/kg donor weight for donors <18 years.
We found this trial at
1
site
425 E River Pkwy # 754
Minneapolis, Minnesota 55455
612-624-2620
Phone: 612-273-2800
Masonic Cancer Center at University of Minnesota The Masonic Cancer Center was founded in 1991....
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials